NMN / NAD+ precursors
Preclinical · 5 studies cited · 2 min · Updated 2026-08-14
In short: NAD+ is genuinely depleted in osteoarthritic cartilage, and restoring it with precursors like NMN protected cartilage in rodent models. But no human NMN trial has ever measured a joint endpoint — zero trials, zero registered — and part of the same NAD+ pathway (extracellular NAMPT) is actively catabolic in joint tissue. Anyone taking NMN for joints is extrapolating from rodents.
NAD+ declines with age, and chondrocytes depend on NAD+-consuming enzymes — most relevantly the deacetylase SIRT1. Mice whose cartilage lacks Sirt1 develop accelerated osteoarthritis under mechanical stress and ageing, with increased chondrocyte death. A 2025 multi-model study sharpened the case: NAD+ is depleted in human OA cartilage, and restoring it — with precursors including NMN, or by overexpressing the synthesis enzyme NMNAT1 — suppressed cartilage degradation in rodent models. NMN is a direct NAD+ precursor, hence the supplementation hypothesis.
The complication the marketing skips
The NAD+ axis in joints is not uniformly protective. NAMPT (visfatin), the NAD+ salvage enzyme, is catabolic when acting extracellularly in cartilage: it drives prostaglandin E2 release and matrix degradation in chondrocytes. "Raise NAD+, help cartilage" is an oversimplification — it is an open question whether oral NMN feeds protective intracellular chondrocyte NAD+ or harmful extracellular NAMPT signalling in synovium, or reaches joint tissue meaningfully at all.
The human evidence — none of it about joints
For joints: none. The only PubMed hits for NMN and osteoarthritis are animal and mechanistic papers, and no registered human trial has cartilage endpoints. What human NMN trials exist are cited here for safety and biology only:
Yoshino 2021 (Science, n=25 prediabetic postmenopausal women, 250 mg/day, 10 weeks) increased skeletal-muscle insulin sensitivity — a single tissue-level outcome in a small, specific population, with several other endpoints unchanged. Yi 2023 (n=80 healthy middle-aged adults, 300–900 mg/day, 60 days, manufacturer-sponsored) showed dose-dependent blood NAD+ rises, a modest six-minute-walk improvement, and no safety concerns. A separate 4-week study found 1,250 mg/day well tolerated. None of this says anything about cartilage.
Dosing & practical notes
No joint-relevant dose exists. Human trials used 250–1,250 mg/day, and blood NAD+ rises reliably from about 300 mg/day. Note the US regulatory wrinkle: since 2022 the FDA's position has been that NMN is excluded from the dietary-supplement definition (a drug-investigation preclusion), though it remains widely sold. Industry sponsorship is pervasive in the human NMN literature.
Contradicting evidence & limitations
The central limitation is the total absence of human joint data. Beyond that: the key rodent efficacy paper is very recent, single-group, and used rodent dosing; human NMN trials show inconsistent functional benefits across endpoints; and the NAMPT/visfatin literature is a standing caution that this pathway cuts both ways in joint tissue.
Safety
Short-term human trials up to 1,250 mg/day for up to 60 days report no significant adverse events. Long-term safety is unknown, and theoretical concerns — NAD+ and the senescent-cell secretome, tumour metabolism — remain unresolved.
What I take from it
This is the best-credentialed preclinical story in the section: real human tissue findings, a named driver (PARP14-driven NAD+ consumption), and rodent rescue experiments. It is still a story without a single human joint measurement. The gating study — any NMN or NR trial with knee pain, function, or MRI endpoints — has not even been registered.
Why this tier? No human joint outcomes exist for NMN — no trials and no registered studies with cartilage endpoints. The pathway case (NAD+/SIRT1 in chondrocytes) is real and the 2025 rodent efficacy data are direct but single-group and unreplicated; human RCTs at 250–900 mg/day establish safety and NAD+ raising only, and are largely manufacturer-sponsored.